Choose monotherapy with VYZULTA in appropriate patients who:

Are starting their open-angle glaucoma or ocular hypertension journey and may benefit from a powerful first-line IOP-lowering treatment1–3

Have inadequately controlled IOP on their current regimen—including1,2,4–6

  • Monotherapy
  • Combination therapy regimens (PGA and non-PGA)
  • Post SLT*

Provide powerful IOP reduction and excellent tolerability with VYZULTA to appropriate patients in your practice, including patients with both high and low baseline IOP.1-3,7

*In clinical trials, patients with a history of SLT in either eye >90 days prior to study entry could be enrolled.5,6

See real-world results of
VYZULTA in a newly diagnosed glaucoma patient.

VYZULTA VISIONARIES

American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting April 5, 2024: Roundtable discussion

American Society of Cataract and Refractive Surgery (ASCRS)
Annual Meeting April 5, 2024: Roundtable discussion

Highlights captured from a roundtable discussion of clinicians' perspectives on monotherapy with VYZULTA.

DOWNLOAD ARTICLEdownload
Roundtable discussion

Optometry’s Meeting® June 20, 2024: Roundtable discussion

Optometrists discuss why they choose VYZULTA for a diverse range of patient types.

DOWNLOAD ARTICLEdownload

IOP=intraocular pressure; PGA=prostaglandin analog; SLT=selective laser trabeculoplasty.

INDICATION

VYZULTA® (latanoprostene bunod ophthalmic solution), 0.024% is indicated for the reduction of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.

IMPORTANT SAFETY INFORMATION

  • Increased pigmentation of the iris and periorbital tissue (eyelid) can occur. Iris pigmentation is likely to be permanent
  • Gradual changes to eyelashes, including increased length, increased thickness, and number of eyelashes, may occur. These changes are usually reversible upon treatment discontinuation
  • Use with caution in patients with a history of intraocular inflammation (iritis/uveitis). VYZULTA should generally not be used in patients with active intraocular inflammation
  • Macular edema, including cystoid macular edema, has been reported during treatment with prostaglandin analogs. Use with caution in aphakic patients, in pseudophakic patients with a torn posterior lens capsule, or in patients with known risk factors for macular edema
  • There have been reports of bacterial keratitis associated with the use of multiple-dose containers of topical ophthalmic products that were inadvertently contaminated by patients
  • Contact lenses should be removed prior to the administration of VYZULTA and may be reinserted 15 minutes after administration
  • Most common ocular adverse reactions with incidence ≥2% are conjunctival hyperemia (6%), eye irritation (4%), eye pain (3%), and instillation site pain (2%)

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

Please click here to see full Prescribing Information.

Expand

INDICATION

VYZULTA® (latanoprostene bunod ophthalmic solution), 0.024% is indicated for the reduction of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.

IMPORTANT SAFETY INFORMATION

  • Increased pigmentation of the iris and periorbital tissue (eyelid) can occur. Iris pigmentation is likely to be permanent

References: 1. VYZULTA. Prescribing Information. Bausch & Lomb Inc. 2. Weinreb RN, Ong T, Scassellati Sforzolini B, Vittitow JL, Singh K, Kaufman PL; VOYAGER Study Group. A randomised, controlled comparison of latanoprostene bunod and latanoprost 0.005% in the treatment of ocular hypertension and open-angle glaucoma: the VOYAGER study. Br J Ophthalmol. 2015;99(6):738-745. 3. Weinreb RN, Liebmann JM, Martin KR, Kaufman PL, Vittitow JL. Latanoprostene bunod 0.024% in subjects with open-angle glaucoma or ocular hypertension: pooled phase 3 study findings. J Glaucoma. 2018;27(1):7-15. 4. Gordon MO, Beiser JA, Brandt JD, et al. The Ocular Hypertension Treatment Study: baseline factors that predict the onset of primary open-angle glaucoma. Arch Ophthalmol. 2002;120(6):714-720, 829-830. 5. LUNAR. ClinicalTrials.gov identifier: NCT01749930. Updated November 21, 2018. Accessed May 27, 2025. 6. APOLLO. ClinicalTrials.gov identifier: NCT01749904. Updated November 7, 2018. Accessed May 27, 2025. 7. Kawase K, Vittitow JL, Weinreb RN, Araie M; JUPITER Study Group. Long-term safety and efficacy of latanoprostene bunod 0.024% in Japanese subjects with open-angle glaucoma or ocular hypertension: the JUPITER study. Adv Ther. 2016;33(9):1612-1627.